Drugs / CART-BCMA/CS1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05950113 | Mar 2024 → Mar 2027 | plasma cell myeloma | Jonsson Comprehensive Cancer Center | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CART-BCMA/CS1 | “Patients then receive the CART-BCMA/CS1 infusion IV on I-Day -0 on study.” NCT05950113 ↗ |
| Action | Deplete | “These engineered CART-BCMA/CS1 cells may kill MM cells.” NCT05950113 ↗ |
| Route | Intravenous | “CART-BCMA/CS1 infusion IV” NCT05950113 ↗ |